Iobenguane sulfate (MIBG sulfate) is a high-affinity substrate for cholera toxin that disrupts cellular mono(ADP-ribosylation). Radioiodinated Iobenguane sulfate is used clinically as a tumor-targeted radiopharmaceutical for diagnosing and treating adrenergic tumors.

Iobenguane sulfate is an effective effector of endogenous mono(ADP-ribosyl) transferases of turkey and human erythrocyte membranes, exerting its effect in the μM concentration range. Iobenguane sulfate (2-20 μg/ml; 72 hours) suppresses cell growth in a panel of human and mouse leukemia, melanoma, fibrosarcoma, and neuroblastoma cell lines.

Iobenguane sulfate (20 mg/kg; i.p.; daily on days 3-6) displays antitumor activity. Iobenguane sulfate testes for its toxicity on male strain AF (N1Ell5) mice with 5 daily injections. At 50 mg/kg body weight, all animals died after 1-4 doses and 4/16 animals died on a schedule of 44 mg/kg. The survival of male strain AF mice inoculates with N1E115 neuroblastoma and treats according to NIH protocols for new drug testing with 9 daily injections of Iobenguane sulfate (40 mg/kg), Marking prolongation of survival but no cures were observed.